カーディガン
KARD
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.24 | $0 | -$51M |
| 2026 Q1 | -0.90 | $0 | -$59M |